Core Insights - Stephens has initiated coverage on Pyxis Oncology Inc, emphasizing the company's technology platform for next-gen antibody-drug conjugates (ADCs) with improved potency, stability, and tolerability [1] - The lead drug, PYX-201, targets Extradomain-B Fibronectin (EDB+FN) in tumor stroma and delivers a toxic payload into the tumor microenvironment [1] - The analyst has given an Overweight rating with a price target of $13 [1] ADC Technology Potential - The ADC technology has demonstrated strong potential, with recent successes enhancing confidence in market growth [2] - Pyxis has shown that proteases and acidic conditions in the tumor stroma can effectively break down the payload linker, similar to cellular absorption processes [2] Clinical Trial Updates - The company is set to announce results from the first phase of its human clinical trial for PYX-201, which targets various solid tumors, with updates expected this month [3] - Positive results, including partial or complete responses and a favorable safety profile at doses above 3.6 mg/kg, are anticipated [3] Financial Position - As of June 30, 2024, Pyxis Oncology reported cash and cash equivalents of $157.2 million, which includes restricted cash and short-term investments [4] - The current financial resources are projected to fund operations into the second half of 2026 [4] - The stock price of PYXS was noted at $4.42, reflecting a 12.2% change at the last check [4]

Core Viewpoint - Pyxis Oncology (NASDAQ:PYXS) is an antibody and antibody-drug conjugate (ADC) developer with a focus on clinical trials for its drug PYX-201, which is expected to have data readouts in fall 2024, indicating potential investment opportunities based on upcoming clinical results [1][2][3] Clinical Development - The timeline for data from the phase 1 trial of PYX-201 remains stable, suggesting reduced risk of further delays in reporting results [2] - The company has dosed 72 patients in the dose escalation study for PYX-201 across various cancer types, with expectations for objective responses at higher doses [4] - PYX-201's development is part of a pipeline focused on difficult-to-treat tumors, with additional data from another drug, PYX-106, anticipated by the end of 2024 [3] Competitive Landscape - Philogen S.p.A. is highlighted as a competitor with a successful pipeline targeting extra domain B of fibronectin, which may provide context for PYX-201's potential efficacy [5] Financial Overview - As of June 30, 2024, PYXS had $155.7 million in cash and equivalents, expected to fund operations into the second half of 2026, with a net loss of $17.3 million reported for Q2'24 [6] - The company had 58,942,243 shares outstanding and a market cap of $214.5 million, translating to a share price of $3.64 [6] Investment Outlook - The potential for a stock run-up is noted as data readouts approach in fall 2024, with two significant opportunities for positive results from PYX-201 and PYX-106 [7] - Year-end cash is estimated at $132 million, or approximately $2.24 per share, which may limit downside risk [7]

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Septem ...

Financial Position - As of June 30, 2024, Pyxis Oncology had cash and cash equivalents totaling $157.2 million, expected to fund operations into the second half of 2026[6]. - Total assets as of June 30, 2024, were $208.4 million, an increase from $173.7 million at the end of 2023[11]. - The outstanding number of shares of common stock as of August 14, 2024, was 58,942,243[7]. Revenue and Expenses - Total revenues for the six months ended June 30, 2024, were $16.1 million, primarily from royalty revenues and the sale of royalty rights[10]. - Research and development expenses for Q2 2024 were $13.9 million, up from $11.4 million in Q2 2023, primarily due to increased clinical trial-related expenses[6]. - General and administrative expenses decreased to $6.1 million in Q2 2024 from $6.7 million in Q2 2023[7]. - The net loss for Q2 2024 was $17.3 million, or ($0.29) per common share, compared to a net loss of $15.9 million, or ($0.41) per common share, in Q2 2023[7]. Clinical Trials - A total of 72 subjects have been dosed in the ongoing Phase 1 trial of PYX-201, focusing on various difficult-to-treat cancers[3]. - The company expects to announce preliminary data from the Phase 1 trial of PYX-201 in fall 2024, including efficacy and safety results[4]. - PYX-106, another clinical candidate, has dosed 33 subjects in its Phase 1 trial, with preliminary data expected by year-end 2024[5].

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple t ...

Core Insights - Pyxis Oncology, Inc. is focused on developing next-generation therapeutics for difficult-to-treat cancers [5] - The company has granted restricted stock units and stock options to five newly hired employees as part of its 2022 Inducement Plan [1][2] Employee Compensation - A total of 89,530 restricted stock units and 111,913 stock options were granted to new employees [1] - The stock options have a ten-year term with an exercise price of $3.31, which is the closing price of the company's common stock on June 28, 2024 [2] - The vesting schedule for the stock options includes 25% vesting on the first anniversary and the remaining shares vesting monthly over the following 36 months [2] Company Overview - Pyxis Oncology is a clinical-stage company developing therapeutics such as PYX-201 and PYX-106, targeting solid tumors [5] - The company's therapeutic candidates aim to directly kill tumor cells and address cancer-related pathologies that contribute to proliferation and immune evasion [5] - Pyxis Oncology employs novel strategies in its antibody-drug conjugate and immuno-oncology programs to target a wide range of solid tumors resistant to current treatments [5]

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) ...

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.33, delivering a surprise of 32.65%. Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40881 Pyxis Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 83-1160910 | | --- | --- | | (State or other jurisdiction of incorpo ...

Exhibit 99.1 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 May 14, 2024 PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Dr. Sullivan added, "We plan to dose an additional 16 patients with a focus on five tumor types of interest based on an assessment of factors including immunohistochemistry target expression, stromal volume, unmet medical need, and clinical judgment. Patient recruitment at these dose levels focuses on head and neck squamous c ...